Ceritinib Bests Chemo for Untreated ALK⁺ NSCLC Available to Purchase

Patients with ALK-positive non–small cell lung cancer may soon have a new first-line treatment option in ceritinib, which outperformed chemotherapy in a phase III study. However, toxicity issues remain a problem for ceritinib, and another next-generation ALK inhibitor, alectinib, is more likely to become the drug of choice for untreated patients.